This patient case player contains anonymized real-world patient cases provided by practicing dermatologists and adapted for use by AbbVie. Patient cases provide visual illustrations showing the effects of SKYRIZI^® (risankizumab) treatment at various points in time. A case study is a clinical observation of a singular patient experience. Clinical course and patient outcomes will vary.

SKYRIZI^® (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SKYRIZI^® (risankizumab), alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).¹

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.